45 results on '"Loeffler M"'
Search Results
2. Phase equilibrium investigations and thermodynamic modelling of the ZrO2-Ta2O5 system
3. The Coastal Genesis 2 research programme: Outputs, Outcomes and Impact
4. Ga contamination in silicon by Focused Ion Beam milling: Dynamic model simulation and Atom Probe Tomography experiment
5. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
6. Iterative Finite Element Scheme for Magnetoelectric Energy Harvesters
7. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
8. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
9. Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis
10. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
11. Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?
12. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
13. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma
14. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
15. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
16. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
17. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial
18. Preparation and characterisation of Pt–Ru model electrodes for the direct methanol fuel cell
19. Crystallite growth of nanocrystalline transition metals studied in situ by high temperature synchrotron X-ray diffraction
20. New preparation technique and characterisation of nanostructured catalysts for polymer membrane fuel cells
21. Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF
22. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease
23. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury
24. 360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
25. 470P - A phase I study of tinostamustine in patients (pts) with advanced solid tumours
26. The filling of carbon nanotubes with magnetoelectric Cr 2O 3
27. Distributed energy system simulation of a vehicle
28. 1615O - Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry
29. Mortality and morbidity following hip fractures related to hospital thromboprophylaxis policy
30. Consultant-led triaging service for fracture clinic: An innovative way of improving patient safety and clinical care?
31. CYR61 down-modulation sensitizes prostate cancer cells to zoledronic acid and docetaxel: A new anti-cancer strategy
32. Alkyl Phosphates as Cosmetic Emulsifiers: A Contribution to Non-ethoxylated Emulsifiers
33. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
34. Consolidation radiotherapy to bulky disease in aggressive non Hodgkin's lymphoma. Results of the NHL B-94 trial of the German high grade NHL study group (DSHNHL)
35. Model based development of the BEACOPP regimen for advanced stage Hodgkin’s disease
36. BEACOPP: A new regimen for advanced Hodgkin’s disease
37. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
38. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease
39. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease
40. Is stem length important in uncemented endoprostheses?
41. Workshop I: Review on prognostic factors
42. Workshop III: Recommendations for future clinical trials
43. 158 Long term treatment of intermediate risk myelodys-plastic syndrome with rhG-CSF and rhEPO: Interim report of an ongoing randomized phase III trial
44. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
45. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.